Lianhuan Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for the lactulose oral solution approved and issued by the State Drug Administration. The registration classification is classified as a category 4 chemicals, which is equivalent to passing the consistent evaluation of the quality and efficacy of generic drugs. The drug is suitable for chronic or habitual constipation, regulates the physiological rhythm of the colon; hepatic encephalopathy, and is used to treat and prevent hepatic coma or pre-coma states. In 2025, the sales volume of this drug in hospitals above level II nationwide will reach 563 million yuan. The company invested about 5.297 million yuan in research and development of this drug. As of the disclosure date of this announcement, the company and its subsidiaries have obtained a total of 12 production approvals in 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.